Prazosin dosage and administration: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 3: Line 3:
{{CMG}}; {{AE}} {{AK}}
{{CMG}}; {{AE}} {{AK}}


==Dosage And Administration==
==Dosage and Administration==


The dose of MINIPRESS should be adjusted according to the patient's individual blood pressure response. The following is a guide to its administration:
The dose of MINIPRESS should be adjusted according to the patient's individual blood pressure response. The following is a guide to its administration:

Revision as of 19:56, 12 March 2014

Prazosin
Prazosin®, Minipress® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Prazosin
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

Dosage and Administration

The dose of MINIPRESS should be adjusted according to the patient's individual blood pressure response. The following is a guide to its administration:

Initial Dose

1 mg two or three times a day (see WARNINGS.)

Maintenance Dose

Dosage may be slowly increased to a total daily dose of 20 mg given in divided doses. The therapeutic dosages most commonly employed have ranged from 6 mg to 15 mg daily given in divided doses. Doses higher than 20 mg usually do not increase efficacy, however a few patients may benefit from further increases up to a daily dose of 40 mg given in divided doses. After initial titration some patients can be maintained adequately on a twice daily dosage regimen.

Use With Other Drugs

When adding a diuretic or other antihypertensive agent, the dose of MINIPRESS should be reduced to 1 mg or 2 mg three times a day and retitration then carried out.

Concomitant administration of MINIPRESS with a PDE-5 inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension; therefore, PDE-5 inhibitor therapy should be initiated at the lowest dose in patients taking MINIPRESS.[1]


References

  1. "MINIPRESS (PRAZOSIN HYDROCHLORIDE) CAPSULE [PFIZER LABORATORIES DIV PFIZER INC]". Retrieved 6 March 2014.